Increase in non-transferrin bound iron and the oxidative stress status in epilepsy patients treated using valproic acid monotherapy

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 4, 2011, Pages 268-276

  Ounjaijean, S ^a,b   Westermarck, T ^c   Partinen, M ^a   Plonka Poltorak, E ^d   Kaipainen, P ^c   Kaski, M ^c   Fucharoen, S ^e   Srichairatanakool, S ^b   Atroshi, F ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c Rinnekoti Foundation Finland   (Finland)

^d Provincial Hospital Rzeszow   (Poland)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Epilepsy; Lipid peroxidation; Non transferrin bound iron; Trace elements; Valproic acid

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; COPPER; FERRITIN; IRON; SELENIUM; TRANSFERRIN; VALPROIC ACID; ZINC;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; ENZYME ACTIVITY; EPILEPSY; FEMALE; FERRITIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; IRON BLOOD LEVEL; IRON METABOLISM; LIPID PEROXIDATION; MALE; MONOTHERAPY; NON TRANSFERRIN BOUND IRON BLOOD LEVEL; OXIDATIVE STRESS; SELENIUM BLOOD LEVEL; SIDE EFFECT; TRACE METAL BLOOD LEVEL; ZINC BLOOD LEVEL;

ADULT; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; IRON; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; VALPROIC ACID;

EID: 79955949063     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201466     Document Type: Article

References (51)

1. Hamed SA, Abdellah MM. Trace elements and electrolytes homeostasis and their relation to antioxidant enzyme activity in brain hyperexcitability of epileptic patients. J Pharmacol Sci. 2004; 96: 349-359. (Pubitemid 40144050)
2. Lomnitski L, Nyska A, Shohami E, Chen Y, Michaelson DM. Increased levels of intracellular iron in the brains of ApoE-deficient mice with closed head injury. Exp Toxicol Pathol. 2000; 52: 177-183. (Pubitemid 30313586)
3. Sharma V, Babu PP, Singh A, Singh S, Singh R. Iron-induced experimental cortical seizures: electroencephalographic mapping of seizure spread in the subcortical brain areas. Seizure. 2007; 16: 680-690. (Pubitemid 350018664)
4. Willmore LJ, Ueda Y. Posttraumatic epilepsy: hemorrhage, free radicals and the molecular regulation of glutamate. Neurochem Res. 2009; 34: 688-697.
5. Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, Jansen EH, Jauhiainen K, Sturm B, Porter JB, Scheiber-Mojdehkar B, von Bonsdorff L, Cabantchik ZI, Hider RC, Swinkels DW. Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005; 341: 241-250. (Pubitemid 40724808)
6. Choi BH. Oxygen, antioxidants and brain dysfunction. Yonsei Med J. 1993; 34: 1-10.
7. Gutteridge JM, Westermarck T, Santavuori P. Iron and oxygen radicals in tissue damage: implications for the neuronal ceroid lipofuscinoses. Acta Neurol Scand. 1983; 68: 365-370. (Pubitemid 14214456)
8. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Saf. 1996; 15: 378-393. (Pubitemid 27007318)
9. Singh S, Hider RC, Porter JB. Adirect method for quantification of non-transferrin-bound iron. Anal Biochem. 1990; 186: 320-323. (Pubitemid 20153513)
10. Ounjaijean S, Thephinlap C, Khansuwan U, Phisalapong C, Fucharoen S, Porter JB, Srichairatanakool S. Effect of green tea on iron status and oxidative stress in iron-loaded rats. Med Chem. 2008; 4: 365-370.
11. Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993; 57: 715-724.
12. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996; 239: 70-76.
13. Hirate M, Takeda A, Tamano H, Enomoto S, Oku N. Distribution of trace elements in the brain of EL (epilepsy) mice. Epilepsy Res. 2002; 51: 109-116. (Pubitemid 35283882)
14. Heiskala H, Gutteridge JM, Westermarck T, Alanen T, Santavuori P. Bleomycin-detectable iron and phenanthroline-detectable copper in the cerebrospinal fluid of patients with neuronal ceroidlipofuscinoses. Am J Med Genet. 1988; 5 (Suppl): 193-202.
15. Kurekci AE, Alpay F, Tanindi S, Gokcay E, Ozcan O, Akin R, Isimer A, Sayal A. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy. Epilepsia. 1995; 36: 600-604.
16. Armutcu F, Ozerol E, Gurel A, Kanter M, Vural H, Yakinci C, Akyol O. Effect of long-term therapy with sodium valproate on nail and serum trace element status in epileptic children. Biol Trace Elem Res. 2004; 102: 1-10. (Pubitemid 40105001)
17. Verrotti A, Basciani F, Trotta D, Pomilio MP, Morgese G, Chiarelli F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res. 2002; 48: 71-75. (Pubitemid 34127718)
18. Kuzuya T, Hasegawa T, Shimizu K, Nabeshima T. Effect of anti-epileptic drugs on serum zinc and copper concentrations in epileptic patients. Int J Clin Pharmacol Ther Toxicol. 1993; 31: 61-65. (Pubitemid 23088085)
19. Barbeau A, Donaldson J. Zinc, taurine, and epilepsy. Arch Neurol. 1974; 30: 52-58.
20. Hamed SA, Abdellah MM, El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci. 2004; 96: 465-473. (Pubitemid 40144068)
21. Kaji M, Ito M, Okuno T, Momoi T, Sasaki H, Yamanaka C, Yorifuji T, Mikawa H. Serum copper and zinc levels in epileptic children with valproate treatment. Epilepsia. 1992; 33: 555-557.
22. Takeda A. Zinc homeostasis and functions of zinc in the brain. Biometals. 2001; 14: 343-351. (Pubitemid 34066637)
23. Ilhan A, Ozerol E, Gulec M, Isik B, Ilhan N, Akyol O. The comparison of nail and serum trace elements in patients with epilepsy and healthy subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28: 99-104. (Pubitemid 37553144)
24. Sozuer DT, Barutcu UB, Karakoc Y, Yalcin E, Onen S. The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol. 1995; 6: 265-269. (Pubitemid 26083447)
25. Manser WW, Khan MA, Hasan KZ. Trace element studies on Karachi population. Part IV: Blood copper, zinc, magnesium and lead levels in psychiatric patientswith depression,mental retardation and seizure disorders. J Pak Med Assoc. 1989; 39: 269-274.
26. Ramaekers VT, Calomme M, Vanden Berghe D, Makropoulos W. Selenium deficiency triggering intractable seizures. Neuropediatrics. 1994; 25: 217-223. (Pubitemid 24304611)
27. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics. 1998; 29: 195-201. (Pubitemid 28396070)
28. Zachara BA, Pawluk H, Bloch-Boguslawska E, Sliwka KM, Korenkiewicz J, Skok Z, Ryc K. Tissue level, distribution, and total body selenium content in healthy and diseased humans in Poland. Arch Environ Health. 2001; 56: 461-466. (Pubitemid 34008249)
29. Wasowicz W, Gromadzinska J, Rydzynski K, Tomczak J. Selenium status of low-selenium area residents: Polish experience. Toxicol Lett. 2003; 137: 95-101. (Pubitemid 36044041)
30. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993; 262: 689-695. (Pubitemid 23350687)
31. Youdim MB, Ben-Shachar D, Yehuda S, Riederer P. The role of iron in the basal ganglion. Adv Neurol. 1990; 53: 155-162.
32. Shoham S, Youdim MB. The effects of iron deficiency and iron and zinc supplementation on rat hippocampus ferritin. J Neural Transm. 2002; 109: 1241-1256.
33. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta. 2009; 1790: 606-614.
34. Stankiewicz JM, Brass SD. Role of iron in neurotoxicity: a cause for concern in the elderly? Curr Opin Clin Nutr Metab Care. 2009; 12: 22-29.
35. Ikeda M. Iron overload without the C282Y mutation in patients with epilepsy. J Neurol Neurosurg Psychiatry. 2001; 70: 551-553. (Pubitemid 32269701)
36. Stovner LJ, Hagen K,Waage A, Bjerve KS. Hereditary haemochromatosis in two cousins with cluster headache. Cephalalgia. 2002; 22: 317-319. (Pubitemid 41701451)
37. Gorter JA, Mesquita AR, van Vliet EA, da Silva FH, Aronica E. Increased expression of ferritin, an iron-storage protein, in specific regions of the parahippocampal cortex of epileptic rats. Epilepsia. 2005; 46: 1371-1379.
38. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism.Transfus Sci. 2000; 23: 185-192.
39. Dennison HA. Limitations of ferritin as a marker of anemia in end stage renal disease. ANNAJ. 1999; 26: 409-414.
40. Lee DH, Jacobs DR. Serum markers of stored body iron are not appropriate markers of health effects of iron: a focus on serum ferritin. Med Hypotheses. 2004; 62: 442-445.
41. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996; 88: 705-713. (Pubitemid 26240403)
42. Srichairatanakool S, Ounjaijean S, Thephinlap C, Khansuwan U, Phisalpong C, Fucharoen S. Ironchelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin. 2006; 30: 311-327. (Pubitemid 43977333)
43. Thompson KJ, Shoham S, Connor JR. Iron and neurodegenerative disorders. Brain Res Bull. 2001; 55: 155-164. (Pubitemid 32722155)
44. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004; 5: 863-873. (Pubitemid 39482155)
45. Carbonell T, Rama R. Iron, oxidative stress and early neurological deterioration in ischemic stroke. Curr Med Chem. 2007; 14: 857-874. (Pubitemid 46863616)
46. Ikeda Y, Ikeda K, Long DM. Protective effect of the iron chelator deferoxamine on cold-induced brain edema. J Neurosurg. 1989; 71: 233-238. (Pubitemid 19194941)
47. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P-450 - catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science. 1987; 235: 890-893. (Pubitemid 17019127)
48. Yis U, Seckin E, Kurul SH, Kuralay F, Dirik E. Effects of epilepsy and valproic acid on oxidant status in children with idiopathic epilepsy. Epilepsy Res. 2009; 84: 232-237.
49. Verrotti A, Scardapane A, Franzoni E, Manco R, Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res. 2008; 78: 171-177.
50. Schulpis KH, Lazaropoulou C, Regoutas S, Karikas GA, Margeli A, Tsakiris S, Papassotiriou I. Valproic acid monotherapy induces DNAoxidative damage. Toxicology. 2006; 217: 228-232. (Pubitemid 41773839)
51. Yuksel A, Cengiz M, Seven M, Ulutin T. Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies. J Child Neurol. 2001; 16: 603-606. (Pubitemid 32798887)